AML or CML dendritic cells (DC) for the in vitro generation of leukemia-reactive cytotoxic T cells.

被引：0
|
作者：
Brouwer, RE [1 ]
Bongaerts, R [1 ]
Van der Hoorn, MAWG [1 ]
Willemze, R [1 ]
Falkenburg, JHF [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
752
引用
收藏
页码：175A / 175A
页数：1
相关论文
共 50 条
  • [21] Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential
    Liepert, Anja
    Grabrucker, Christine
    Kremser, Andreas
    Dreyssig, Julia
    Ansprenger, Christian
    Freudenreich, Markus
    Kroell, Tanja
    Reibke, Roland
    Tischer, Johanna
    Schweiger, Cornelia
    Schmid, Christoph
    Kolb, Hans-Jochem
    Schmetzer, Helga
    CELLULAR IMMUNOLOGY, 2010, 265 (01) : 23 - 30
  • [22] Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro
    Syme, R
    Bryan, T
    Duggan, P
    Bajwa, R
    Stewart, D
    Glück, S
    STEM CELLS AND DEVELOPMENT, 2004, 13 (02) : 211 - 221
  • [23] Generation of dendritic cells expressing BCR/ABL from FACS sorted CD34+ chronic myeloid leukemia (CML) precursor cells.
    Smit, WM
    Rijnbeek, M
    vanBergen, CAM
    dePaus, RA
    Landegent, JE
    Willemze, R
    Falkenburg, JHF
    BLOOD, 1995, 86 (10) : 1278 - 1278
  • [24] Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC/leukemia fusion cells as a tumor vaccine for AML
    Rosenblatt, J
    Stone, R
    Lenahan, C
    Wu, Z
    Vasir, B
    DeAngelo, DJ
    Galinsky, I
    Miller, K
    Levine, JD
    Joyce, R
    Kufe, D
    Avigan, D
    BLOOD, 2005, 106 (11) : 782A - 782A
  • [25] CTL lines reactive to CML and AML cells by priming with autologous dendritic cells derived from leukemic clone.
    Narita, M
    Takahashi, M
    Toba, K
    Liu, A
    Furukawa, T
    Aoki, S
    Fuse, I
    Koike, T
    Aizawa, Y
    BLOOD, 2000, 96 (11) : 43B - 43B
  • [26] Generation of leukemia derived dendritic cells in patients with acute leukemia and CML blastic crisis.
    Takahashi, M
    Liu, A
    Zheng, Z
    Furukawa, T
    Toba, K
    Narita, M
    Koike, T
    Aizawa, Y
    BLOOD, 1999, 94 (10) : 78A - 78A
  • [27] FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes
    Brackertz, B.
    Conrad, H.
    Daniel, J.
    Kast, B.
    Kroenig, H.
    Busch, D. H.
    Adamski, J.
    Peschel, C.
    Bernhard, H.
    BLOOD CANCER JOURNAL, 2011, 1 : e11 - e11
  • [28] FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes
    B Brackertz
    H Conrad
    J Daniel
    B Kast
    H Krönig
    D H Busch
    J Adamski
    C Peschel
    H Bernhard
    Blood Cancer Journal, 2011, 1 : e11 - e11
  • [29] Depletion of in-vivo activated regulatory T cells followed by synchronized specific in-vitro activation allows the rapid isolation of leukemia-reactive T cells for immunotherapy
    Jedema, I
    Steeneveld, E
    Hoogendoorn, M
    Willemze, R
    Falkenburg, JHF
    BLOOD, 2004, 104 (11) : 88A - 89A
  • [30] Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
    Falkenburg, JHF
    Wafelman, AR
    Joosten, P
    Smit, WM
    van Bergen, CAM
    Bongaerts, R
    Lurvink, E
    van der Hoorn, M
    Kluck, P
    Landegent, JE
    Kluin-Nelemans, HC
    Fibbe, WE
    Willemze, R
    BLOOD, 1999, 94 (04) : 1201 - 1208
12345